Literature DB >> 6194927

Assessment of methods to identify sources of interindividual pharmacokinetic variations.

E S Vesell, M B Penno.   

Abstract

The advantages and limitations of the 2 most commonly used methods to investigate interindividual pharmacokinetic variations are reviewed. The first method is based on pharmacokinetic comparisons made after repeated administration of a model drug such as antipyrine, before, during and after imposition of a carefully controlled environmental perturbation. A principal virtue of the test is the use of each subject as a control. Subjects are usually under near basal conditions with respect to factors capable of altering hepatic drug-metabolising capacity. Exceedingly sensitive, the test yields highly reproducible results. It has been useful as a research tool in identifying environmental factors for which dose-response curves can be generated and compared. However, the test requires careful selection and control of subjects, and it may be hazardous to extrapolate results to subjects under different, non-basal, environmental conditions. This method most frequently involves antipyrine as the test compound, but other drugs can and have been used. The results disclose that many host factors that influence antipyrine disposition also affect the disposition of other drugs metabolised by hepatic mixed-function oxidases. Recent refinement of the antipyrine test involves measurement of the rate constant for formation of each of the 3 main metabolites of antipyrine. Sensitivity and specificity of the test are increased through examination of the effect of each factor on a separate hepatic cytochrome P-450. Due to the labouriousness of this procedure and its requirement for several days of urine collection from each subject, metabolite analysis will probably remain an experimental method not applicable for screening populations. The second method involves a particular model based on multiple regression analysis. Relying on correlations with historical data of a qualitative nature, previous applications of this method have been retrospective, rather than prospective. Several such correlations could not be confirmed in normal subjects under the conditions of a controlled prospective experiment. Thus, prospective studies need to be performed to check results obtained with this method. The model used appears to enjoy certain advantages, including speed, simplicity, and ease of execution.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194927     DOI: 10.2165/00003088-198308050-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  106 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

Authors:  E S Vesell; G T Passananti; P A Glenwright; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

3.  Genetic and environmental factors affecting ethanol metabolism in man.

Authors:  E S Vesell; J G Page; G T Passananti
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

4.  Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity.

Authors:  D J Greenblatt; M Divoll; D R Abernethy; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

5.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

6.  Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol.

Authors:  S E Smith; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

7.  Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Authors:  L G Sultatos; B H Dvorchik; E S Vesell; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

8.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Genetic control of drug levels in man: phenylbutazone.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-03-29       Impact factor: 47.728

10.  Anomalous results of studies on drug interaction in man. I. Nortriptyline and antipyrine.

Authors:  E S Vesell; G T Passananti; K C Aurori
Journal:  Pharmacology       Date:  1975       Impact factor: 2.547

View more
  21 in total

Review 1.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Elimination of cotinine from body fluids.

Authors:  D W Sepkovic; N J Haley
Journal:  Am J Public Health       Date:  1988-06       Impact factor: 9.308

3.  Plasma antipyrine half-life can be determined from urine data.

Authors:  J O Atiba; G Taylor; R A Pershe; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 4.  The genomics of cardiovascular disorders: therapeutic implications.

Authors:  P Ferrari; G Bianchi
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

5.  Elimination of cotinine from body fluids: disposition in smokers and nonsmokers.

Authors:  N J Haley; D W Sepkovic; D Hoffmann
Journal:  Am J Public Health       Date:  1989-08       Impact factor: 9.308

6.  Effects of cimetidine and ranitidine on the pharmacokinetics of quinine.

Authors:  S Wanwimolruk; M Sunbhanich; M Pongmarutai; P Patamasucon
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

7.  Simplified approaches to the determination of antipyrine pharmacokinetic parameters.

Authors:  J M Scavone; D J Greenblatt; G T Blyden; J S Harmatz; P J Graziano
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

8.  The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.

Authors:  K Groen; M A Horan; N A Roberts; R S Gulati; B Miljkovic; E J Jansen; V Paramsothy; D D Breimer; C F van Bezooijen
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 9.  Drug disposition in obese humans. An update.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 10.  Genetic factors in neurotoxicology and neuropharmacology: a critical evaluation of the use of genetics as a research tool.

Authors:  M F Festing
Journal:  Experientia       Date:  1991-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.